Decitabine--bedside to bench.

[1]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[2]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[3]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[4]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[5]  J. Issa,et al.  DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.

[6]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[7]  E. Estey,et al.  Adult acute myeloid leukemia. , 2006, Mayo Clinic proceedings.

[8]  S. Sanche,et al.  5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. , 2006, Leukemia research.

[9]  B. Dörken,et al.  Decitabine: Where Is the Target?. , 2005 .

[10]  D. Berry,et al.  CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study. , 2005 .

[11]  J. Issa,et al.  Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML). , 2005 .

[12]  M. Lübbert,et al.  Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. , 2005, Cancer research.

[13]  K. Bhalla.  Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Rosner,et al.  Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome , 2005 .

[16]  J. Issa,et al.  Hypomethylation induction in MDS after treatment with decitabine at three different doses , 2005 .

[17]  R. Pazdur,et al.  Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.

[18]  W. Reik,et al.  Epigenetic reprogramming in mammals. , 2005, Human molecular genetics.

[19]  N. Eberhardt,et al.  Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. , 2005, Gynecologic oncology.

[20]  M. Lübbert,et al.  Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine). , 2004, Leukemia research.

[21]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[22]  F. Prósper,et al.  Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. , 2004, Blood.

[23]  I. Flinn,et al.  Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[25]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[26]  S. Kitano,et al.  Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. , 2004, The American journal of pathology.

[27]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[28]  J. Issa,et al.  Epigenetic changes in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[29]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[30]  I. Bièche,et al.  Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  T. Kinoshita,et al.  Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes , 2003, Leukemia.

[32]  J. Issa,et al.  Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia , 2003, Cancer.

[33]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[34]  M. Maio,et al.  5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? , 2003, Blood.

[35]  J. Herman,et al.  Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. , 2003, Cancer cell.

[36]  E. Li.  Chromatin modification and epigenetic reprogramming in mammalian development , 2002, Nature Reviews Genetics.

[37]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[38]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[39]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Weber,et al.  Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. , 2002, Current opinion in investigational drugs.

[41]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[42]  E. Selker,et al.  A histone H3 methyltransferase controls DNA methylation in Neurospora crassa , 2001, Nature.

[43]  S. Baylin,et al.  Dnmt3a and Dnmt3b Are Transcriptional Repressors That Exhibit Unique Localization Properties to Heterochromatin* , 2001, The Journal of Biological Chemistry.

[44]  Keith D Robertson,et al.  DNA methylation, methyltransferases, and cancer , 2001, Oncogene.

[45]  T. Kouzarides,et al.  Dnmt3a binds deacetylases and is recruited by a sequence‐specific repressor to silence transcription , 2001, The EMBO journal.

[46]  J. Issa,et al.  Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.

[47]  K. Akashi,et al.  Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. , 2001, Blood.

[48]  S. Hirohashi,et al.  DNA methyltransferase expression and DNA methylation of CPG islands and peri‐centromeric satellite regions in human colorectal and stomach cancers , 2001, International journal of cancer.

[49]  S. Baylin,et al.  DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci , 2000, Nature Genetics.

[50]  Peter L. Jones,et al.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.

[51]  N. Heisterkamp,et al.  Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. , 2000, Blood.

[52]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[53]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  T. Kinoshita,et al.  Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes , 2000, Leukemia.

[55]  Luke Hughes-Davies,et al.  DNA methyltransferase Dnmt1 associates with histone deacetylase activity , 2000, Nature Genetics.

[56]  S. Nass,et al.  Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells , 1999, Oncogene.

[57]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[58]  A. Marzo,et al.  Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. , 1999, Cancer research.

[59]  P. Laird,et al.  CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. , 1999, Cancer research.

[60]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[61]  E. Li,et al.  Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases , 1998, Nature Genetics.

[62]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[63]  T. Kinoshita,et al.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997, Blood.

[64]  P. Laird,et al.  COBRA: a sensitive and quantitative DNA methylation assay. , 1997, Nucleic acids research.

[65]  P. Jones,et al.  Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). , 1997, Nucleic acids research.

[66]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[67]  M. Link,et al.  Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.

[68]  R. Willemze,et al.  A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). , 1997, Leukemia.

[69]  E. Estey,et al.  Decitabine studies in chronic and acute myelogenous leukemia. , 1997, Leukemia.

[70]  P. Néve,et al.  Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome , 1997, Leukemia.

[71]  P. Hornsby,et al.  Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification. , 1996, Nucleic acids research.

[72]  A. Feinberg,et al.  Limited up-regulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[74]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[75]  S. Baylin,et al.  Increased cytosine DNA-methyltransferase activity during colon cancer progression. , 1993, Journal of the National Cancer Institute.

[76]  F. Mandelli,et al.  Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. , 1993, Leukemia.

[77]  R. Willemze,et al.  Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. , 1993, Leukemia.

[78]  S. Monfardini,et al.  5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. , 1993, Leukemia.

[79]  V. Zagonel,et al.  5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. , 1993, Leukemia.

[80]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Szyf,et al.  Growth regulation of mouse DNA methyltransferase gene expression. , 1991, The Journal of biological chemistry.

[82]  S. Baylin,et al.  High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[83]  B. Wold,et al.  Genomic sequencing and methylation analysis by ligation mediated PCR. , 1989, Science.

[84]  J. Skoda,et al.  Azapyrimidine nucleosides: metabolism and inhibitory mechanisms. , 1985, Advances in enzyme regulation.

[85]  G. Rivard,et al.  Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. , 1985, Pharmacology & therapeutics.

[86]  A. Fusco,et al.  5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. , 1984, Blood.

[87]  J. Christman,et al.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.

[88]  Burdon Rh,et al.  DNA methylation in eukaryotes. , 1982 .

[89]  Kun-Tsan Lin,et al.  Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. , 1981, Leukemia research.

[90]  M. Ehrlich,et al.  Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. , 1980, Nucleic acids research.

[91]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[92]  R. Shapiro,et al.  Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. , 1973, The Journal of biological chemistry.

[93]  J. Veselý,et al.  Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine. , 1972, Biochemical pharmacology.

[94]  L H Li,et al.  Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. , 1970, Cancer research.

[95]  L. Li,et al.  Phase specificity of 5-azacytidine against mammalian cells in tissue culture. , 1970, Cancer research.